Last updated on October 2018

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Brief description of study

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

Clinical Study Identifier: NCT03085810

Contact Investigators or Research Sites near you

Start Over

Reference Study ID: MA30143

VU Medisch Centrum; Afdeling Neurologie
Amsterdam, Netherlands
  Connect »